The Technical Analyst
GBS Inc. [GBS]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Medical - Devices
GBS Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.58% $0.473
/ 27 okt 2022 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.434 mill |
| EPS: | -0.502 |
| P/E: | -0.943 |
| Earnings Date: | Aug 31, 2022 |
| SharesOutstanding: | 0.916 mill |
| Avg Daily Volume: | 0.0516 mill |
| RATING 2022-12-28 |
|---|
| B+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.943 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.943 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.404 - 0.542 ( +/- 14.58%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-10-04 | Sakiris Spiro Kevin | Buy | 0 | |
| 2023-10-04 | Towers Christopher | Buy | 9 090 | Common Stock |
| 2023-10-04 | Towers Christopher | Buy | 9 090 | Common Stock Warrants (Series E) |
| 2023-10-04 | Towers Christopher | Buy | 9 090 | Common Stock Warrants (Series F) |
| 2023-10-04 | Sakiris Spiro Kevin | Buy | 112 727 | Common Stock |
| INSIDER POWER |
|---|
| 95.44 |
| Last 80 transactions |
| Buy: 892 204 | Sell: 7 603 867 |
Forecast:
01:40 - $0.463
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.473 (-1.58% ) |
| Volume | 0.0090 mill |
| Avg. Vol. | 0.0516 mill |
| % of Avg. Vol | 17.51 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GBS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GBS
GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Latest Press Releases
2022-08-29 09:05:00 - Press Release
Gbs Inc. To Present Fourth Quarter And Full Year 2022 Financial Results And Recent Corporate Update On August 31
Company to host conference call & webcast at 4:30 p.m. et company to host conference call & webcast at 4:30 p.m. et
2022-05-16 16:05:00 - Press Release
Gbs Inc. To Present At The H.c. Wainwright Global Investment Conference
New york, may 16, 2022 (globe newswire) -- gbs inc. (nasdaq: gbs), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that, today announced that dr. steven boyages, gbs' interim ceo and chairman of the board, along with other management team members will participate at the h.c. wainwright global investment conference being held may 23–26, 2022 and invites investors to participate via virtual one-on-one meetings. please see additional details below:
2022-05-03 09:05:00 - Press Release
Gbs Inc. To Present Third Quarter 2022 Financial Results And Recent Corporate Update On May 10
Company to host conference call & webcast at 4:30 p.m. et company to host conference call & webcast at 4:30 p.m. et
2022-03-07 08:30:00 - Press Release
Gbs Inc. To Participate In The Upcoming March investor Conferences
New york, march 07, 2022 (globe newswire) -- gbs (nasdaq: gbs), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that dr. steven boyages, gbs' interim ceo and chairman of the board, along with other management team members will participate in the following conferences in march and invites investors to participate in one-on-one meetings. please see additional details below:
2022-02-07 08:30:00 - Press Release
Gbs Inc. To Present Second Quarter 2022 Financial Results And Recent Corporate Update On February 10
Company to host conference call & webcast at 4:30 p.m. et company to host conference call & webcast at 4:30 p.m. et
Latest News
2022-09-01 18:40:27 - Seeking Alpha
GBS, Inc. (GBS) Q4 2022 Earnings Call Transcript
GBS, Inc. (NASDAQ:GBS ) Q4 2022 Earnings Conference Call August 31, 2022 4:30 PM ET Company Participants Steven Boyages - Chairman and Interim CEO Spiro Sakiris - CFO Conference Call Participants John Vandermosten - Zacks SCR Operator Greetings, and thank you for joining us for GBS, Inc's Fourth Quarter and Fiscal Yearend 2022 Financial and Business Update Conference Call. Currently all participants are in a listen-only mode.
2022-08-29 09:05:00 - GlobeNewsWire
GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31
Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET
2022-05-16 16:05:00 - GlobeNewsWire
GBS Inc. to Present at the H.C. Wainwright Global Investment Conference
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that, today announced that Dr. Steven Boyages, GBS' interim CEO and Chairman of the Board, along with other management team members will participate at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022 and invites investors to participate via virtual one-on-one meetings. Please see additional details below:
2022-05-14 23:28:18 - Seeking Alpha
GBS Inc.'s (GBS) CEO Dr. Steven Boyages on Q3 2022 Results - Earnings Call Transcript
GBS Inc. (NASDAQ:GBS ) Q3 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Dr. Steven Boyages - Chairman and Interim CEO Spiro Sakiris - Chief Financial Officer Conference Call Participants John Vandermosten - Zacks Operator Greetings. And welcome to the GBS Inc. Third Quarter 2022 Earnings Conference Call.
2022-05-03 09:05:00 - GlobeNewsWire
GBS Inc. to Present Third Quarter 2022 Financial Results and Recent Corporate Update on May 10
Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET
2022-03-21 16:37:51 - PennyStocks
4 Trending Penny Stocks to Add to Your Watchlist Right Now
Are these trending penny stocks on your watchlist right now? The post 4 Trending Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-03-07 08:30:00 - GlobeNewsWire
GBS Inc. to Participate in the Upcoming March Investor Conferences
NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that Dr. Steven Boyages, GBS' interim CEO and Chairman of the Board, along with other management team members will participate in the following conferences in March and invites investors to participate in one-on-one meetings. Please see additional details below:
2022-02-10 21:15:20 - Seeking Alpha
GBS Inc. (GBS) CEO Steven Boyages on Q2 2022 Results - Earnings Call Transcript
2022-02-07 08:30:00 - GlobeNewsWire
GBS Inc. to Present Second Quarter 2022 Financial Results and Recent Corporate Update on February 10
Company to Host Conference Call & Webcast at 4:30 p.m. ET Company to Host Conference Call & Webcast at 4:30 p.m. ET
2021-12-20 07:10:00 - GlobeNewsWire
GBS Inc. to Participate in the Upcoming January Virtual Investor Conferences
NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that Dr. Steven Boyages, GBS' interim CEO and Chairman of the Board, along with other management team members will participate in the following conferences in January and invites investors to participate in virtual one-on-one meetings. Please see additional details below: